$271 Million is the total value of INTERNATIONAL BIOTECHNOLOGY TRUST PLC's 62 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PTCT | New | PTC Therapuetics COM | $9,050,000 | – | 240,493 | +100.0% | 3.34% | – |
| ALKS | New | ALKERMES PLC | $8,502,000 | – | 233,000 | +100.0% | 3.14% | – |
| WVE | New | WAVE LIFE SCIENCES LTD | $5,632,000 | – | 145,000 | +100.0% | 2.08% | – |
| RTRX | New | Retrophin Inc | $4,703,000 | – | 208,000 | +100.0% | 1.74% | – |
| INSM | New | INSMED INC | $3,198,000 | – | 110,000 | +100.0% | 1.18% | – |
| AKCA | New | AKCEA THERAPEUTICS INC | $2,110,000 | – | 74,608 | +100.0% | 0.78% | – |
| GTHX | New | G1 Therapeutics Inc | $1,631,000 | – | 98,482 | +100.0% | 0.60% | – |
| ASND | New | ASCENDIS PHARMA A Ssponsored adr | $1,624,000 | – | 13,800 | +100.0% | 0.60% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $1,590,000 | – | 21,700 | +100.0% | 0.59% | – |
| MYOK | New | Myokardia INC | $1,559,000 | – | 30,000 | +100.0% | 0.58% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $1,544,000 | – | 30,000 | +100.0% | 0.57% | – |
| GBT | New | Global Blood Therapeutics | $1,481,000 | – | 28,000 | +100.0% | 0.55% | – |
| XLRN | New | ACCELERON PHARMA INC | $1,396,000 | – | 30,000 | +100.0% | 0.52% | – |
| MYGN | New | Myriad Genetics inc | $1,273,000 | – | 38,365 | +100.0% | 0.47% | – |
| IFRX | New | INFLARX NV | $1,223,000 | – | 32,500 | +100.0% | 0.45% | – |
| MLND | New | Millendo Therapeutics Inc | $925,000 | – | 61,860 | +100.0% | 0.34% | – |
| MNTA | New | MOMENTA PHARMACEUTICALS INC | $792,000 | – | 54,580 | +100.0% | 0.29% | – |
| TCDA | New | Tricida Inc | $751,000 | – | 19,066 | +100.0% | 0.28% | – |
| ARNA | New | Arena Pharmaceuticals Inc | $740,000 | – | 16,500 | +100.0% | 0.27% | – |
| DERM | New | Dermira Inc | $407,000 | – | 30,000 | +100.0% | 0.15% | – |
| MGNX | New | MACROGENICS INC | $342,000 | – | 19,000 | +100.0% | 0.13% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GILEAD SCIENCES INC COMMO | 28 | Q3 2023 | 9.3% |
| INCYTE CORP INC COM | 28 | Q3 2023 | 7.9% |
| BIOMARIN PHARMACEUTICALS INC | 28 | Q3 2023 | 7.5% |
| REGENERON PHARMS. | 27 | Q3 2023 | 9.0% |
| BIOGEN INC COMMON STOCK | 26 | Q3 2023 | 8.7% |
| VERTEX PHARMS. | 25 | Q3 2023 | 8.4% |
| AMGEN INC COM | 25 | Q3 2023 | 7.9% |
| NEUROCRINE BIOSCIENCES INC | 25 | Q3 2023 | 6.9% |
| ALYNYLAM PHARMACEUTICALS INC | 25 | Q3 2023 | 6.7% |
| IONIS PHARMS. | 25 | Q3 2023 | 4.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Altus Pharmaceuticals Inc. | February 12, 2009 | ? | ? |
| MICROMET, INC. | February 14, 2008 | 1,907,390 | 4.7% |
| EPIMMUNE INC | February 15, 2005 | 1,279,659 | 8.0% |
| ESSENTIAL THERAPEUTICS INC | April 29, 2003 | 2,500,000 | 11.7% |
| TARGETED GENETICS CORP /WA/ | April 18, 2003 | ? | ? |
| ESSENTIAL THERAPEUTICS INC | November 05, 2001 | 11 | 13.0% |
| ONYX PHARMACEUTICALS INC | October 15, 2001 | 11 | 13.0% |
| CORVAS INTERNATIONAL INC | October 12, 2001 | 11 | 13.0% |
| RIBOZYME PHARMACEUTICALS INC | October 05, 2001 | 11 | 13.0% |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-18 |
| 13F-HR | 2023-02-01 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-20 |
| 13F-HR | 2022-02-15 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
View INTERNATIONAL BIOTECHNOLOGY TRUST PLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.